Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Wednesday

Zevra Therapeutics (NASDAQ:ZVRA) is set to issue its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.20). Zevra Therapeutics had a negative return on equity of 68.41% and a negative net margin of 167.69%. The firm had revenue of $13.22 million for the quarter, compared to analysts’ expectations of $13.35 million. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Trading Up 1.5 %

Shares of ZVRA traded up $0.07 during midday trading on Thursday, hitting $4.67. The stock had a trading volume of 11,056 shares, compared to its average volume of 242,352. The stock’s 50 day moving average is $5.54 and its 200 day moving average is $5.36. The firm has a market cap of $202.82 million, a PE ratio of -3.82 and a beta of 1.87. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.18 and a quick ratio of 1.18. Zevra Therapeutics has a 1 year low of $3.89 and a 1 year high of $7.28.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ZVRA shares. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, April 3rd. Maxim Group upped their target price on Zevra Therapeutics from $12.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. William Blair reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Tuesday, March 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a report on Monday, April 1st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $19.50.

About Zevra Therapeutics

Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.